NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
Clinical Trials
5 trialsNCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT06863831 2025-03-07
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Enrolling by invitation
NCT06429865 2024-05-28
Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
Changhai Hospital
Phase NA Enrolling by invitation
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation